Critical role of the vascular endothelial cell in health and disease: A review article

Journal of Veterinary Emergency and Critical Care

Volumn 14, Issue 2, 2004, Pages 84-99

  Duffy, Todd C ^a,b   Kirby, Rebecca ^a   Rudloff, Elke ^a  

^a Animal Emergency Center   (United States)

^b Indianapolis Veterinary Specialists   (United States)

Author keywords

Coagulation; Inflammation; Vascular endothelium; Vascular permeability; Vasomotor tone

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; CORTICOSTEROID; ENDOTOXIN ANTIBODY; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMMUNOMODULATING AGENT; PENTOXIFYLLINE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BLOOD CLOTTING; BLOOD VESSEL TONE; CAPILLARY FLOW; CELL CULTURE; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL MEMBRANE PERMEABILITY; CLINICAL TRIAL; CRITICAL ILLNESS; DISEASE COURSE; EDEMA; HEALTH STATUS; HEMOSTASIS; HUMAN; HYPOXEMIA; HYPOXIA; INFLAMMATION; INFLAMMATORY DISEASE; INTERSTITIUM; LEUKOCYTE; MEDICAL LITERATURE; MEDLINE; MULTIPLE ORGAN FAILURE; NONHUMAN; REVIEW; RISK ASSESSMENT; THROMBOSIS; TISSUE OXYGENATION; VASCULAR ENDOTHELIUM; VETERINARY MEDICINE;

ANIMALIA;

EID: 13444252385     PISSN: 14793261     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1534-6935.2004.00116.x     Document Type: Review

References (170)

1. Unemori EN, Bouhana KS, Werb Z. Vectorial secretion of extracellular matrix proteins, matrix-degrading proteinases, and tissue inhibitor of matalloproteinases by endothelial cells. J Biol Chem 1990; 265(1):445-451.
2. Guyton AC, Hall JE. The microcirculation and the lymphatic systems: capillary fluid exchange, interstitial fluid, and lymph flow, In: Textbook of Medical Physiology, 9th edn. Philadephia: W.B. Saunders; 1996, pp. 183-196.
3. Dejana E, Corada M, Lampugnani MG. Endothelial cell-to-cell junctions. FASEB J 1995; 9(10):910-918.
4. Dejana E. Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest 1996; 98(9):1949-1953.
5. Copley AL. The endothelial fibrin lining, fibrinogen gel clotting, and the endothelium-blood interface. Ann NY Acad Sci 1983; 416:377-396.
6. Pries AR, Secomb TW, Gaehtgens P. The endothelial surface layer. Pflügers Arch - Eur J Physiol 2000; 440(5):653-666.
7. Davies PF, Barbee KA, Volin MV, et al. Spatial relationships in early signaling events of flow-mediated endothelial mechanotransduction. Ann Rev Physiol 1997; 59:527-549.
8. Secomb TW, Hsu R, Pries AR. Effect of endothelial glycocalyx on oxygen transport from capillaries to tissue: a theoretical model (abstract). FASEB J 1999; 13:A25.
9. Henry CB, Duran WN, DeFouw DO. Permselectivity of angiogenic microvessels following alteration of the endothelial fiber matrix by oligosaccharides. Microvasc Res 1997; 53(2):150-155.
10. Schneeberer EE, Lynch RD, Neary BA. Interaction of native and chemically modified albumin with pulmonary microvascular endothelium. Am J Physiol 1990; 258(2 Part 1):L89-L98.
11. Adamson RH. Permeability of frog mesenteric capillaries after partial pronase digestion of endothelial glycocalyx. J Physiol 1990; 428:1-13.
12. Linjen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 1997; 39(4):343-350.
13. Mertens G, Cassiman JJ, Van den Berghe H, et al. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem 1992; 26728:20435-20443.
14. Silvestro L, Ruikin C, Sommer F, et al. Platelet-activating factor-induced endothelial cell expression of adhesion molecules and modulation of surface glycocalyx, evaluated by electron spectroscopy chemical analysis. Semin Thromb Hemost 1994; 20(2):214-220.
15. Skinner MP, Lucas CM, Burns GF, et al. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem 1991; 266(9):5371-5374.
16. Garcia JGN, Schaphorst KL. Regulation of endothelial cell gap formation and paracellular permeability. J Invest Med 1995; 43(2):117-126.
17. Anderson R. Caveolae: where incoming and outgoing messengers meet. Proc Natl Acad Sci USA 1993; 90(23):10909-10913.
18. Parton R, Simons K. Digging into caveolae. Science 1995; 269(5229):1398-1399.
19. Stahl A, Mueller BM. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol 1995; 129(2):335-344.
20. Garcia-Cardena G, Oh P, Liu J, et al. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci USA 1996; 93(13):6448-6453.
21. Feron O, Belhassen L, Kobzid L, et al. Endothelial nitric oxide synthase targeting to caveolae: specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem 1996; 271(37):22810-22814.
22. 2+-calmodulin and caveolin. J Biol Chem 1997; 272(25):15583-15586.
23. Ju H, Zou R, Venema VJ, et al. Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J Biol Chem 1997; 272(30):18522-18525.
24. Fujimoto TA, Miyawaki A, Mikoshiba K. Inositol 1,4,5-triphosphate receptor-like protein in the plasmelemmal caveolae is linked to actin filaments. J Cell Sci 1995; 108(Part 1):7-15.
25. McNiff JM, Gil J. Secretion of Weibel-Palade bodies observed in extra-alveolar vessels of rabbit lung. J Appl Physiol 1983; 54(5):1284-1286.
26. Datta YH, Ewenstein BM. Regulated secretion in endothelial cells: biology and clinical applications. Thromb Hemost 2001; 86(5):1148-1155.
27. Ewenstein BM, Warhol MH, Handin RI, et al. Composition of von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol 1987; 104(5):1423-1433.
28. Silverstein RL. The vascular endothelium, In: Gallin JI, Snyderman R eds. Inflammation: Basic Principles and Clinical Correlates, 3rd edn. Philadelphia: Lippicott, Williams and Wilkins; 1999, pp. 207-224.
29. Risau W. Differentiation of endothelium. FASEB J 1995; 9(10):926-933.
30. Garcia JGN, Verin AD, Schaphorst KL. Regulation of thrombin-mediated endothelial cell contraction and permeability. Semin Thromb Hemost 1996; 22(4):309-315.
31. Lui J, Oh P, Horner T, et al. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J Biol Chem 1997; 272(11):7211-7222.
32. Ghinea N, Eskenasy M, Simionescu M, et al. Endothelial albumin binding proteins are membrane-associated components exposed on the cell surface. J Biol Chem 1989; 264(9):4755-4758.
33. Ghinea N, Fixman A, Alexandra D, et al. Identification of albumin-binding proteins in capillary endothelial cells. J Cell Biol 1988; 107(1):231-239.
34. Milici AJ, Watrous NE, Stukenbrok H, et al. Transcytosis of albumin in capillary endothelium. J Cell Biol 1987; 105(6):2603-2612.
35. Schnitzer JE, Carley WW, Palade GE. Specific albumin binding to microvascular endothelium in culture. Am J Physiol 1988; 254(3 Part 2):H425.
36. Schnitzer JE, Carley WW, Palade GE. Albumin interacts specifically with a 6OkDa microvascular endothelial glycoproteins. Proc Natl Acad Sci USA 1988; 85(18): 6773-6777.
37. Wagner R, Chen S-C. Transcapillary transport of solute bv the endothelial vesicular system: evidence from thin serial section analysis. Microvasc Res 1991; 42(1):139-150.
38. Alexander JS, Elrod JW. Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 2002; 200(60):561-574.
39. Wisse E, De Zanger RB, Jacobs R, et al. Scanning electron microscopy observations on the structure of portal veins, sinusoids and central veins. Scanning Electron Micros 1983; 3:1441-1452.
40. Wisse E, De Zanger RB, Charels K, et al. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal well and the space of Disse. Hepatology 1985; 5(4):683-692.
41. Perry VH, Anthony DC, Bolton SJ, et al. The blood-brain barrier and the inflammatory response. Mol Med Today 1997; 3(8):335-341.
42. Schnittler A, Wilke A, Gress T, et al. Role of actin and myosin in the control of paracellular permeability in pig, rat, and human vascular endothelium. J Physiol 1990; 431:379-401.
43. Michel CC. Transport of macromolecules through microvascular walls. Cardio Res 1996; 32(4):644-653.
44. Majno G, Palade GE. Studies on inflammation. I. The effect of serotonin and histamine on vascular permeability: an electron microscopic study. J Biophys Biochem Cytol 1961; 11:571-605.
45. Lum H, Malik AB. Regulation of vascular endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 1994; 267(3 Part 1):L223-L241.
46. Allport JR, Muller WA, Luscinskas FW. Monocytes induce reversible focal changes in vascular endothelial cadherin complex during transendothelial migration under flow. J Cell Biol 2000; 148(1):203-216.
47. Wachtel M, Frei K, Ehler E, et al. Occludin proeolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. J Cell Sci 1999; 112(Part 23):4347-4356.
48. Busse R, Mulsch A, Fleming I, et al. Mechanisms of nitric oxide release from the vascular endothelium. Circulation 1993; 87(Suppl V):V18-V25.
49. Weksler BB, Marcus AJ, Jaffe EA. Synthesis of prostaglandin 12 (prostacyclin) by culture human and bovine endothelial cells. Proc Natl Acad Sci USA 1977; 74(9):3922-3926.
50. Vane R, Anggard E, Botting M. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323(1):27-36.
51. Baenziger NL, Force LE, Becherer PR. Histamine stimulates prostacyclin synthesis in culture human endothelial cells. Biochem Biophys Res Commun 1980; 92(4):1435-1440.
52. Cramer EB, Pologe L, Pawlowski NA, et al. Leukotriene C4 promotes prostacyclin synthesis by human endothelial cells. Proc Natl Acad Sci USA 1983; 80(13):4109-4113.
53. Endo H, Akahoshi T, Kashiwazaki S. Additive effects of IL-1 and TNF on induction of prostacyclin synthesis in human vascular endothelial cells. Biochem Biophys Res Commun 1988; 156(2): 1007-1014.
54. Rossi V, Breviario F, Ghezzi P, et al. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229(4709):174-176.
55. Shuman MA, Isaacs JD, Maerowitz T, et al. Endothelial cell and platelet binding sites for thrombin. Ann NY Acad Sci 1981; 370:57-66.
56. Weksler BB. Regulation of prostaglandin synthesis in human vascular cells. Ann NY Acad Sci 1987; 509:142-148.
57. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta: inhibition of endothelium-derived nitric oxide. J Clin Invest 1990; 85(2):587-590.
58. Levin ER. Endothelin. N Engl J Med 1995; 333(6):356-363.
59. Tsukahara H, Ende H, Magazine HI, et al. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells: receptor coupling to nitric oxide synthase. J Biol Chem 1994; 269(34):21778-21785.
60. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332(6163):411-415.
61. Hexum TD, Hoeger C, Rivier JE, et al. Characterization of endothelin secretion by vascular endothelial cells. Biochem Biophys Res Comm 1990; 167(1):294-300.
62. Levin ER. Endothelins. N Engl J Med 1995; 333(6):356-363.
63. Yoshizumi M, Kurihara H, Morita T, et al. Interleukin-1 increases the production of endothelin-1 by cultured endothelial cells. Biochem Biophys Res Comm 1990; 166(1):324-329.
64. Yoshizumi M, Kurihara H, Sugiyama T, et al. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Comm 1989; 161(2):859-864.
65. Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction. Curr Opin Crit Care 2002; 8(3):242-250.
66. Li H, Chen SJ, Chen YF, et al. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Phys 1994; 77(3):1451-1459.
67. Lush CW, Kvietys PR. Microvascular dysfunction in sepsis. Microcirculation 2000; 7(2):83-101.
68. Bunting S, Gryglewski R, Moncada S, et al. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and celiac arteries and inhibits platelet aggregation. Prostaglandins 1976; 12(6):897-913.
69. Busse R, Luckhoff A, Bassenge E. Endothelium-derived relaxant factor inhibits platelet activation. Naunyn Schmiedbergs Arch Pharmacol 1987; 336(5)566-571.
70. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the vascular endothelial cell. Hypertension 1988; 12(6)530-548.
71. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263(5579):663-665.
72. Marcus AJ, Weksler BB, Jaffe EA, et al. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. J Clin Invest 1980; 66(5):979-986.
73. Randomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2(8567):1057-1058.
74. Mellion BT, Ignarro LJ, Ohlstein EH, et al. Evidence for the inhibitory role of guanosine 3′,5′ monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57(5):946-955.
75. Smith WL. The eicosanoids and their biochemical mechanism of action. Biochem J 1989; 259(2):315-324.
76. Marcum JA, Rosenberg RD. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 1985; 126(1):365-372.
77. Marcum JA, Atha DH, Fritze LMS, et al. Cloned bovine aortic endothelial cells synthesize anticoagulantly active heparan sulfate proteoglycan. J Biol Chem 1986; 261(16):7507-7517.
78. Esmon CT. The regulation of natural anticoagulant mechanisms. Science 1987; 235(4794):1348-1352.
79. Maruyama I, Bill CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics and on syncytioblast of human placenta. J Cell Biol 1985; 101(2):363-371.
80. Heeb MJ, Rosing J, Bakker HM, et al. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91(7):2728-2732.
81. Esmon CT. The endothelial cell protein C receptor. Thromb Hemostasis 2000; 83(5):639-643.
82. Levine EG, Loskutoff DJ. Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators. J Cell Biol 1982; 94(3):631-636.
83. Loskutoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 1977; 74(9):3903-3907.
84. Barnathan ES, Kuo A, Van der Keyl H, et al. Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct bindings sites. J Biol Chem 1988; 263(16):7792-7799.
85. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 1973; 52(11):2757-2764.
86. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci USA 1974; 71(5):1906-1909.
87. Mayadas T, Wagner DD, Simpson PJ. von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation. Blood 1989; 73(3):706-711.
88. Weibel ER, Palade GE. New cytoplasmic components in arterial endothelia. J Cell Biol 1964; 23:101-110.
89. Hannah MJ, Ross W, Jasber K, et al. Biogenesis of Weibel-Palade bodies. Semin Cell Dev Biol 2002; 13(4):313-324.
90. Hattori R, Hamilton KK, McEver RP, et al. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989; 264(15):9053-9060.
91. Levine JD, Harlan JM, Harker LA, et al. Thrombin-mediated release of factor VIII antigen from human umbilical vein endothelial cells in culture. Blood 1982; 60(2):531-534.
92. Reidy MA, Chopek M, Chao S, et al. Injury induces increase of von Willebrand factor in rat endothelial cells. Am J Pathol 1989; 134(4):857-864.
93. Ribes JA, Francis CW, Wagner DD. Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987; 79(1):117-123.
94. Schorer AE, Moldow CF, Rick ME. Interleukin-1 or endotoxin increases the release of von Willebrand factor form human endothelial cells. Br J Haematol 1987; 67(2):193-197.
95. Sporn LA, Marder VJ, Wagner DD. Differing polarity of the constitutive and regulated secretory pathways of von Willebrand factor in endothelial cells. J Cell Biol 1989; 108(4):1283-1289.
96. Wagner DD, Olmstead JB, Marder VJ. Immunolocolonization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982; 95(1):355-360.
97. Drake TA, Morrisey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134(5):1087-1097.
98. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86(8):2839-2843.
99. Bevilacqua MP, Pober JS, Mejeau GR, et al. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160(2):618-623.
100. Bevilacqua MP, Pober JS, Mejeau GR, et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with actions of interleukin-1. Proc Natl Acad Sci USA 1986; 83(12):4533-4537.
101. Brox JH, Østerud E, Bjørklid E, et al. Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets. Br J Haematol 1984; 57(2):239-246.
102. Colucci M, Balconi G, Lorenzet R, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71(6):1893-1896.
103. Edgington TS, Mackman N, Fan ST, et al. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nuov Rev Fr Hematol 1992; 34(Suppl):S15-S27.
104. Geelen S, Bhattacharyya C, Tuomanen E. Induction of procoagulant activity on human endothelial cells by streptococcus pneumoniae. Infect Immunol 1992; 60(10): 4179-4183.
105. Ogawa S, Gerlach H, Esposito C, et al. Hypoxia modulates the barrier and coagulant function of culture bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. J Clin Invest 1990; 85(4):1090-1098.
106. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996; 81(1):1-41.
107. Cerveny TJ, Fass DN, Mann KG. Synthesis of coagulation factor V by cultured aortic endothelium. Blood 1984; 63(6):1467-1474.
108. Annamalai AE, Stewart G, Hansel B, et al. Expression of factor V on human umbilical vein endothelial cells is modulated by cell injury. Arteriosclerosis 1986; 6(2):196-202.
109. Stern DM, Drillings M, Nossel HL, et al. Binding of factors IX and IXa to culture vascular endothelial cells. Proc Natl Acad Sci USA 1983; 80(13):4119-4123.
110. Loskutoff DJ, van Mourik JA, Erickson LA, et al. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80(10):2956-2960.
111. Berrettini M, Schleef RR, Espana F, et al. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system. J Biol Chem 1989; 264(20):11738-11743.
112. Sakata Y, Curriden S, Lawrence D, et al. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82(4):1121-1125.
113. Sakata Y, Loskutoff DJ, Gladson CL, et al. Mechanism of protein C-dependent role of plasminogen activator inhibitor. Blood 1986; 68(6):1218-1223.
114. Zoellner H, Wojta J, Gallicchia M, et al. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells. Comparison with plasminogen activator inhibitor-1 synthesis. Thromb Haemost 1993; 69(2):135-140.
115. Hajjar KA, Nachman RL. Endothelial cell-mediated conversion of Glu-plasminogen to Lys-plasminogen. Further evidence for assembly of the fibrinolytic system on the endothelial cell surface. J Clin Invest 1988; 82(5):1769-1778.
116. Alon R, Feiglson S. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol 2002; 14(2):93-104.
117. Alexander JS, Elrod JW, Park JH. Roles of leukocyte and immune cell junctional proteins. Microcirculation 2001; 8(3):169-179.
118. Breider MA. Endothelium and inflammation. JAVMA 1993; 203(2):300-306.
119. Granger DN, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial adhesion. J Leukoc Biol 1994; 55(5):662-675.
120. Johnston B, Butcher EC. Chemokines in rapid leukocyte adhesion triggering and migration. Semin Immunol 2002; 14(2):83-92.
121. Kubes P. Polymorphonuclear leukocyte - endothelium interactions: a role for pro-inflammatory and antiinflammatory molecules. Can J Physiol Pharmacol 1993; 71(1):88-97.
122. Kubes P. Introduction: the complexities of leukocyte recruitment. Semin Immunol 2002; 14(2):65-72.
123. Luscinskas FW, Ma S, Nusrat A, et al. Leukocyte transendothelial migration: a junctional affair. Semin Immunol 2002; 14(2):105-113.
124. McEver RP. Leukocyte interactions mediated by selectins. Thromb Haemost 1991; 66(1):80-87.
125. Muller WA, Weigl SA, Deng X, et al. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993; 178(2):449-460.
126. Muller WA. Migration of leukocytes across endothelial junctions: some concepts and controversies. Microcirculation 2001; 8(3):181-193.
127. Muller WA. Leukocyte-endothelial cell interactions in the inflammatory response. Lab Invest 2002; 82(5)521-533.
128. Patel KD, Cuvelier SL, Wiehler S. Selectins: critical mediators of leukocyte recruitment. Semin Immunol 2002; 14(2):73-81.
129. Rothlein R. An overview of leukocyte adhesion. Neurology 1997; 49(Suppl 4):S3-S4.
130. Smith CW. Endothelial adhesion molecules and their role in inflammation. Can J Physiol Pharmacol 1993; 71(1):76-87.
131. Smith CW. Possible steps involved in the transition to stationary adhesion of rolling neutrophils: a brief review. Microcirculation 2000; 7(6 Part 1):385-394.
132. Worthylake RA, Burridge K. Leukocyte transendothelial migration: orchestrating the underlying machinery. Curr Opin Cell Biol 2001; 13(5)569-577.
133. Vestweber D. Regulation of endothelial cell contacts during leukocyte extravasation. Curr Opin Cell Biol 2002; 14(5)587-593.
134. Geng JG, Bevilacqua MP, Moore KL, et al. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990; 343(22):757-760.
135. Hattori R, Hamilton KK, Fugate RD, et al. Stimulated secretion of endothelial von Willebrand factor is accompanied by rapid redistribution to the cell surface of the intracellular granule membrane protein GMP-140. J Biol Chem 1989; 264(14):7768-7771.
136. Lorant DE, Patel KD, McIntyre TM, et al. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin. A juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 1991; 115(1): 223-243.
137. Patel KD, Zimmerman GA, Prescott SM, et al. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol 1991; 112(4):749-759.
138. Bevilacqua MP, Pober JS, Mendrick DL, et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987; 84(24):9238-9242.
139. Bevilacqua MP, Stengelin S, Gimbrone MA Jr., et al. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 1989; 243(4895): 1160-1165.
140. Pober JS, Gimbrone MA Jr., Lapierre LA, et al. Two distinct monokines, interleukin-1 and tumor necrosis factor, each independently induce biosynthesis of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 1986; 136(5):1680-1687.
141. Pober JS, Gimbrone MA Jr., Lapierre LA, et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor and immune interferon. J Immunol 1986; 137(6):1893-1896.
142. Subramaniam M, Koedam JA, Wagner DD. Divergent fates of P and E-selectins after their expression on the plasma membrane. Mol Biol Cell 1993; 4(8):791-801.
143. Von Adrian UH, Hansell P, Chambers JD, et al. L-selectin function is required for beta-2 integrin mediated neutrophil adhesion at physiological shear rates in vivo. Am J Physiol 1992; 263(4 Part 2):H1034-H1044.
144. Gerristen ME, Kelley KA, Ligon G, et al. Regulation of the expression of intercellular adhesion molecule-1 (ICAM-1) in cultured human endothelial cells derived from rheumatoid synovium. Arthrit Rheum 1993; 36(5):593-602.
145. Swerlick RA, Garcia-Gonzalez E, Kubota Y, et al. Studies of the modulation of MHC antigens and cell adhesion molecule expression on human dermal microvascular endothelial cells. J Dermatol Immunol 1991; 97(2): 190-196.
146. Carlos TM, Schwartz BR, Kovach NL, et al. Vascular cell adhesion molecule-1 lymphocyte adherence to cytokine activated culture human endothelial cells. Blood 1990; 76(11):965-970.
147. Schleimer RP, Sterbinsky SA, Kaiser J, et al. Il-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. J Immunol 1992; 148(4): 1086-1092.
148. Huang AJ, Manning JE, Bandak M, et al. Endothelial cell cytosolic free calcium regulates neutrophil migration across monolayers of endothelial cells. J Cell Biol 1993; 120(6):1371-1380.
149. Allport JR, Muller WA, Luscinskas FW. Monocytes induce reversible focal changes in vascular endothelial cadherin complex during transendothelial migration under flow. J Cell Biol 2000; 148(1):203-216.
150. Oppenheimer-Marks N, Davis LS, Bogue A, et al. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T-lymphocytes. J Immunol 1991; 147(9):2913-2921.
151. Feng D, Nagy JA, Pyne K, et al. Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J Exp Med 1998; 187(6):903-915.
152. Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. J Am Med Assoc 2000; 283(13):1723-1730.
153. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomized controlled trial of monoclonal antibody to tumor necrosis factor in treatment of septic shock NORASEPT II Study Group. Lancet 1998; 351(9107):929-933.
154. Takeshima R, Kirsch JR, Koehier RC, et al. Monoclonal leukocyte antibody does not decrease the injury of transient focal cerebral ischemia in cats. Stroke 1992; 23(2):247-252.
155. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317(11):653-658.
156. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis: The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336(13):912-918.
157. Vincent JL, Qinghua S, Dubois M. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34(8):1084-1093.
158. Anzueto A, Beale R, Holzapfel L, et al. Multicentre, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88 in patients with septic shock: effect on resolution of shock and survival (abstract). Intensive Care Med 1997; 23:5257.
159. Abraham E, Reinhart K, Svodoba P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29(11):2081-2088.
160. Uchiba M, Okajima K, Murakami K. Effect of various doses of antithrombin III and endotoxin-induced endothelial cell injury and coagulation abnormalities in the rat. Thromb Res 1998; 89(5):233-241.
161. Uchiba M, Okajima K, Murakami K, et al. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270(6 Part 1):L921-L930.
162. Dickenette G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost 1998; 24(1):61-69.
163. Leithäuser B, Schumaker J, Lendemas S, et al. Antithrombin attenuates micro vascular leakage and leukocyte-endothelial interaction in response to endotoxin. Semin Thromb Hemost 2002; 28(Suppl 1):87-94.
164. Okano K, Kokudo Y, Okajima K, et al. Protective effects of antithrombin III supplementation on warm ischemia and reperfusion injury in rat liver. World J Surg 1996; 20(8):1069-1075.
165. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10):699-709.
166. Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286(15):1869-1878.
167. Graninger W, Wenisch C. Pentoxifylline in severe inflammatory response syndrome. J Cardiovas Pharmacol 1995; 25(Suppl 2):S134-S138.
168. De Prost D. Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. J Cardiovas Pharmacol 1995; 25(Suppl 2):S114-S118.
169. Zheng H, Crowley JJ, Chan JC, et al. Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminescence. Am Rev Respir Dis 1990; 142(5):1073-1078.
170. Scalia R, Stalker TJ. Microcirculation as a target for the anti-inflammatory properties of statins. Microcirculation 2002; 9(6):431-442.